share_log

IVD Medical Holding Insiders Selling CN¥24m In Stock Relieved As Market Cap Slides To HK$3.0b

IVD Medical Holding Insiders Selling CN¥24m In Stock Relieved As Market Cap Slides To HK$3.0b

華檢醫療控股內部人士出售2400萬元股票,隨着市值下滑至30億港元
Simply Wall St ·  10/26 07:56

Over the past year, insiders sold CN¥24m worth of IVD Medical Holding Limited (HKG:1931) stock at an average price of CN¥1.48 per share allowing them to get the most out of their money. The company's market cap plunged by HK$390m after price dropped by 11% last week but insiders were able to limit their loss to an extent.

在過去的一年裏,內部人士以平均每股CN¥1.48的價格出售了總值2400萬人民幣的華檢醫療控股有限公司(HKG:1931)股票,使其充分利用了資金。 公司的市值在上週股價下跌11%後暴跎39000萬元,但內部人士能夠在一定程度上限制損失。

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

雖然我們不認爲股東應該簡單地跟隨內部交易,但完全忽略內部交易將是愚蠢的。

IVD Medical Holding Insider Transactions Over The Last Year

過去一年華檢醫療控股公司內部交易情況

In the last twelve months, the biggest single sale by an insider was when the insider, Shen Li, sold HK$24m worth of shares at a price of HK$1.48 per share. That means that even when the share price was below the current price of HK$1.86, an insider wanted to cash in some shares. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 12% of Shen Li's stake. Shen Li was the only individual insider to sell shares in the last twelve months.

在過去的十二個月裏,內部人士中最大的單筆交易是內部人士沈麗以每股HK$1.48的價格出售了價值2400萬港元的股份。 這意味着即使股價低於目前的1.86港元,內部人士也想套現一些股票。 當內部人士以低於目前價格出售股票時,這表明他們認爲較低的價格是公平的。 這讓我們想知道他們對(更高的)最近估值的看法。 請注意,賣方出售股票可能有各種原因,因此我們無法確定他們對股價的看法。 這一單筆交易僅佔沈麗持股的12%。 沈麗是過去十二個月唯一一個賣出股票的個人內部人士。

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

SEHK:1600內部交易成交量:2024年6月5日

big
SEHK:1931 Insider Trading Volume October 25th 2024
SEHK:1931 內幕交易成交量 2024年10月25日

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。

IVD Medical Holding Insiders Are Selling The Stock

華檢醫療持股內部人士正在拋售該股

Over the last three months, we've seen significant insider selling at IVD Medical Holding. In total, insider Shen Li dumped HK$24m worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.

過去三個月,我們在華檢醫療控股看到了重大的內部人士拋售股票的情況。總共,內部人士沈莉在這段時間內拋售了價值2400萬港元的股份,而我們沒有記錄到任何購買行爲。總的來說,這讓我們有點謹慎,但也並非一切的決定因素。

Insider Ownership

內部人員持股情況

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. IVD Medical Holding insiders own 36% of the company, currently worth about HK$1.1b based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

我喜歡查看公司內部人員持有多少股份,以幫助了解他們與內部人員的利益保持一致的程度。高比例的內部人員持股通常會使公司領導更加重視股東利益。 華檢醫療Holding的內部人員持有公司36%的股份,根據最近的股價。目前價值約11億港元。大多數股東都會很高興看到這種內部人員持股情況,因爲這表明管理層的激勵措施與其他股東利益是一致的。

What Might The Insider Transactions At IVD Medical Holding Tell Us?

華檢醫療Holding的內部交易可能告訴我們什麼?

An insider sold IVD Medical Holding shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. But it is good to see that IVD Medical Holding is growing earnings. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing IVD Medical Holding. Case in point: We've spotted 3 warning signs for IVD Medical Holding you should be aware of.

不久前,一名內部人員出售了華檢醫療Holding的股票,但他們沒有買入。 在過去十二個月中,我們的數據沒有顯示任何內部人員買入。但看到華檢醫療Holding的收益增長是好事。該公司擁有較高的內部人員持股,但考慮到股份出售的歷史,我們還是有些猶豫。 除了了解正在進行的內部交易,識別面臨的風險也對華檢醫療Holding有益。 舉例來說:我們發現了華檢醫療Holding存在的3個警示信號,您應該注意。

But note: IVD Medical Holding may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:華檢醫療Holding可能不是最適合購買的股票。所以看看這份免費的有高roe和低債務的有趣公司清單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論